{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:22:56Z","timestamp":1791285776817,"version":"4.1.0"},"reference-count":147,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.nmd.2013.09.011","type":"journal-article","created":{"date-parts":[[2013,9,30]],"date-time":"2013-09-30T15:03:31Z","timestamp":1380553411000},"page":"4-15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":96,"title":["Statin myotoxicity: A review of genetic susceptibility factors"],"prefix":"10.1016","volume":"24","author":[{"given":"M.","family":"Needham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.L.","family":"Mastaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2013.09.011_b0005","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.atherosclerosis.2011.07.007","article-title":"Mechanisms of statin-induced myalgia assessed by physiogenomic associations","volume":"218","author":"Ruano","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.nmd.2013.09.011_b0010","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/BOR.0b013e328314b7b4","article-title":"Genetic predisposition to statin myopathy","volume":"20","author":"Vladutiu","year":"2008","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.nmd.2013.09.011_b0015","first-page":"1421","article-title":"Factors affecting patient compliance with antihyperlipidemic medications in an HMO population","volume":"4","author":"Sung","year":"1998","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.nmd.2013.09.011_b0020","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJM199504273321703","article-title":"Discontinuation of antihyperlipidemic drugs\u2013do rates reported in clinical trials reflect rates in primary care settings?","volume":"332","author":"Andrade","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2013.09.011_b0025","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1592\/phco.30.6.541","article-title":"Statin-associated muscle-related adverse effects: a case series of 354 patients","volume":"30","author":"Cham","year":"2010","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.nmd.2013.09.011_b0030","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/path.2018","article-title":"Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia","volume":"210","author":"Draeger","year":"2006","journal-title":"J Pathol"},{"key":"10.1016\/j.nmd.2013.09.011_b0035","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/S0140-6736(07)60716-8","article-title":"The safety of statins in clinical practice","volume":"370","author":"Armitage","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.nmd.2013.09.011_b0040","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/mus.21817","article-title":"Statin-associated myopathy and its exacerbation with exercise","volume":"42","author":"Meador","year":"2010","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2013.09.011_b0045","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/S0002-9149(03)00820-8","article-title":"Safety of atorvastatin derived from analysis of 44 completed trials in 9416 patients","volume":"92","author":"Newman","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.nmd.2013.09.011_b0050","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.amjcard.2005.07.108","article-title":"Comparative safety of atorvastatin 80mg versus 10mg derived from analysis of 49 completed trials in 14,236 patients","volume":"97","author":"Newman","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.nmd.2013.09.011_b0055","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2013.09.011_b0060","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/j.clinthera.2007.08.022","article-title":"Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients","volume":"29","author":"Nichols","year":"2007","journal-title":"Clin Ther"},{"key":"10.1016\/j.nmd.2013.09.011_b0065","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients\u2013the PRIMO study","volume":"19","author":"Bruckert","year":"2005","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.nmd.2013.09.011_b0070","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jacl.2012.03.003","article-title":"Understanding statin use in America and gaps in patient education (USAGE): an internet-based survey of 10,138 current and former statin users","volume":"6","author":"Cohen","year":"2012","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.nmd.2013.09.011_b0075","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1517\/14740338.2011.540568","article-title":"Statin-induced myopathy: a review and update","volume":"10","author":"Abd","year":"2011","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.nmd.2013.09.011_b0080","doi-asserted-by":"crossref","first-page":"52C","DOI":"10.1016\/j.amjcard.2005.12.010","article-title":"Statin safety: a systematic review","volume":"97","author":"Law","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.nmd.2013.09.011_b0085","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1001\/jama.292.21.2585","article-title":"Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs","volume":"292","author":"Graham","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.nmd.2013.09.011_b0090","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1345\/aph.1G035","article-title":"Differential association between statin exposure and elevated levels of creatine kinase","volume":"39","author":"Chan","year":"2005","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.nmd.2013.09.011_b0095","doi-asserted-by":"crossref","first-page":"69C","DOI":"10.1016\/j.amjcard.2005.12.013","article-title":"An assessment of statin safety by muscle experts","volume":"97","author":"Thompson","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.nmd.2013.09.011_b0100","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0025-6196(11)60897-5","article-title":"Toward \u201cpain-free\u201d statin prescribing: clinical algorithm for diagnosis and management of myalgia","volume":"83","author":"Jacobson","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.nmd.2013.09.011_b0105","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1161\/01.str.0000034125.94759.41","article-title":"ACC\/AHA\/NHLBI clinical advisory on the use and safety of statins","volume":"33","author":"Pasternak","year":"2002","journal-title":"Stroke"},{"key":"10.1016\/j.nmd.2013.09.011_b0110","doi-asserted-by":"crossref","first-page":"579","DOI":"10.2217\/pgs.12.11","article-title":"Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutions","volume":"13","author":"Feng","year":"2012","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.nmd.2013.09.011_b0115","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1006\/taap.1997.8131","article-title":"Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro","volume":"145","author":"Flint","year":"1997","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.nmd.2013.09.011_b0120","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1517\/14740338.5.5.651","article-title":"Statins and myotoxicity: a therapeutic limitation","volume":"5","author":"Tiwari","year":"2006","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.nmd.2013.09.011_b0125","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1146\/annurev.bi.65.070196.001325","article-title":"Protein prenylation: molecular mechanisms and functional consequences","volume":"65","author":"Zhang","year":"1996","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.nmd.2013.09.011_b0130","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1126\/science.7652575","article-title":"An essential role for Rho, Rac, and Cdc42 GTPases in cell cycle progression through G1","volume":"269","author":"Olson","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.nmd.2013.09.011_b0135","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/jcp.10109","article-title":"Ras family genes: an interesting link between cell cycle and cancer","volume":"192","author":"Macaluso","year":"2002","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.nmd.2013.09.011_b0140","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s004240000417","article-title":"Influence of exercise intensity on ERK\/MAP kinase signalling in human skeletal muscle","volume":"441","author":"Widegren","year":"2000","journal-title":"Pflugers Arch"},{"key":"10.1016\/j.nmd.2013.09.011_b0145","doi-asserted-by":"crossref","first-page":"R1716","DOI":"10.1152\/ajpregu.2000.279.5.R1716","article-title":"Effects of exercise on mitogen- and stress-activated kinase signal transduction in human skeletal muscle","volume":"279","author":"Krook","year":"2000","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.nmd.2013.09.011_b0150","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/mus.22236","article-title":"Statin-associated changes in skeletal muscle function and stress response after novel or accustomed exercise","volume":"44","author":"Meador","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2013.09.011_b0155","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/S0026-0495(97)90218-3","article-title":"Lovastatin increases exercise-induced skeletal muscle injury","volume":"46","author":"Thompson","year":"1997","journal-title":"Metabolism"},{"key":"10.1016\/j.nmd.2013.09.011_b0160","doi-asserted-by":"crossref","first-page":"8931","DOI":"10.1073\/pnas.87.22.8931","article-title":"Lovastatin decreases coenzyme Q levels in humans","volume":"87","author":"Folkers","year":"1990","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.nmd.2013.09.011_b0165","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1046\/j.1365-2125.1996.04178.x","article-title":"Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate\/pyruvate ratio","volume":"42","author":"De Pinieux","year":"1996","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.nmd.2013.09.011_b0170","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.ahj.2003.12.037","article-title":"Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors","volume":"147","author":"Jamal","year":"2004","journal-title":"Am Heart J"},{"key":"10.1016\/j.nmd.2013.09.011_b0175","first-page":"23","article-title":"Drug-induced myopathies. An overview of the possible mechanisms","volume":"57","author":"Owczarek","year":"2005","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.nmd.2013.09.011_b0180","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2007.02.049","article-title":"The role of coenzyme Q10 in statin-associated myopathy: a systematic review","volume":"49","author":"Marcoff","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.nmd.2013.09.011_b0185","doi-asserted-by":"crossref","first-page":"581","DOI":"10.7326\/0003-4819-137-7-200210010-00009","article-title":"Statin-associated myopathy with normal creatine kinase levels","volume":"137","author":"Phillips","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.nmd.2013.09.011_b0190","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1001\/archneur.62.11.1709","article-title":"Muscle coenzyme Q10 level in statin-related myopathy","volume":"62","author":"Lamperti","year":"2005","journal-title":"Arch Neurol"},{"key":"10.1016\/j.nmd.2013.09.011_b0195","first-page":"85","article-title":"Mitochondrial alterations in muscle biopsies of patients on statin therapy","volume":"36","author":"Gambelli","year":"2004","journal-title":"J Submicrosc Cytol Pathol"},{"key":"10.1016\/j.nmd.2013.09.011_b0200","first-page":"483","article-title":"Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer","volume":"2","author":"Thibault","year":"1996","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nmd.2013.09.011_b0205","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/j.amjcard.2006.12.063","article-title":"Effect of coenzyme q10 on myopathic symptoms in patients treated with statins","volume":"99","author":"Caso","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.nmd.2013.09.011_b0210","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.amjcard.2007.06.030","article-title":"Coenzyme Q10 does not improve simvastatin tolerability in dyslipidemic patients with prior statin-induced myalgia","volume":"100","author":"Young","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.nmd.2013.09.011_b0215","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0002-9343(93)90129-D","article-title":"Simvastatin-induced rhabdomyolysis followed by a MELAS syndrome","volume":"94","author":"Chariot","year":"1993","journal-title":"Am J Med"},{"key":"10.1016\/j.nmd.2013.09.011_b0220","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1159\/000101287","article-title":"Statins provoking MELAS syndrome. A case report","volume":"57","author":"Thomas","year":"2007","journal-title":"Eur Neurol"},{"key":"10.1016\/j.nmd.2013.09.011_b0225","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2165\/0129784-200808060-00004","article-title":"Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism","volume":"8","author":"Golomb","year":"2008","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.nmd.2013.09.011_b0230","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0005-2760(96)00184-1","article-title":"Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types","volume":"1345","author":"Negre-Aminou","year":"1997","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.nmd.2013.09.011_b0235","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0014-2999(99)00122-3","article-title":"Pro-apoptotic effect of fluvastatin on human smooth muscle cells","volume":"370","author":"Buemi","year":"1999","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.nmd.2013.09.011_b0240","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1161\/01.RES.83.5.490","article-title":"3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture","volume":"83","author":"Guijarro","year":"1998","journal-title":"Circ Res"},{"key":"10.1016\/j.nmd.2013.09.011_b0245","first-page":"3940","article-title":"The muscle-specific ubiquitin ligase atrogin-1\/MAFbx mediates statin-induced muscle toxicity","volume":"117","author":"Hanai","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.nmd.2013.09.011_b0250","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.1503\/cmaj.081785","article-title":"Association between statin-associated myopathy and skeletal muscle damage","volume":"181","author":"Mohaupt","year":"2009","journal-title":"CMAJ"},{"key":"10.1016\/j.nmd.2013.09.011_b0255","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1055\/s-2004-869597","article-title":"Statins and cardiac allograft vasculopathy after heart transplantation","volume":"4","author":"Kobashigawa","year":"2004","journal-title":"Semin Vasc Med"},{"key":"10.1016\/j.nmd.2013.09.011_b0260","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4414\/smw.2001.06144","article-title":"The HMG-CoA reductase inhibitor simvastatin inhibits IFN-gamma induced MHC class II expression in human vascular endothelial cells","volume":"131","author":"Kwak","year":"2001","journal-title":"Swis Med Wkly"},{"key":"10.1016\/j.nmd.2013.09.011_b0265","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.atherosclerosis.2004.02.016","article-title":"Statin-induced immunomodulatory effects on human T cells in vivo","volume":"175","author":"Fehr","year":"2004","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.nmd.2013.09.011_b0270","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.4049\/jimmunol.172.2.1273","article-title":"Potential targets of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor for multiple sclerosis therapy","volume":"172","author":"Nath","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.nmd.2013.09.011_b0275","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nature01158","article-title":"The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease","volume":"420","author":"Youssef","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.nmd.2013.09.011_b0280","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/art.30156","article-title":"Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy","volume":"63","author":"Mammen","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2013.09.011_b0285","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/BOR.0b013e32834b324b","article-title":"Necrotizing autoimmune myopathy","volume":"23","author":"Liang","year":"2011","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.nmd.2013.09.011_b0290","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/mus.21486","article-title":"Immune-mediated necrotizing myopathy associated with statins","volume":"41","author":"Grable-Esposito","year":"2010","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2013.09.011_b0295","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.nmd.2006.10.007","article-title":"Progressive myopathy with up-regulation of MHC-I associated with statin therapy","volume":"17","author":"Needham","year":"2007","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2013.09.011_b0300","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/mus.23854","article-title":"Statin-associated autoimmune myopathy and anti-HMGCR autoantibodies: a review","volume":"48","author":"Mohassel","year":"2013","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2013.09.011_b0305","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s11910-011-0232-9","article-title":"Update on toxic myopathies","volume":"12","author":"Mastaglia","year":"2012","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.nmd.2013.09.011_b0310","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.revmed.2003.10.013","article-title":"Polymyositis induced or associated with lipid-lowering drugs: five cases","volume":"25","author":"Fauchais","year":"2004","journal-title":"Rev Med Intern"},{"key":"10.1016\/j.nmd.2013.09.011_b0315","first-page":"25","article-title":"Pravastatin-associated polymyositis, a case report","volume":"44","author":"Takagi","year":"2004","journal-title":"Rinsho Shinkeigaku"},{"key":"10.1016\/j.nmd.2013.09.011_b0320","first-page":"934","article-title":"Severe polymyositis with simvastatin use","volume":"37","author":"Riesco-Eizaguirre","year":"2003","journal-title":"Rev Neurol"},{"key":"10.1016\/j.nmd.2013.09.011_b0325","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/S0140-6736(05)61628-5","article-title":"Polymyositis associated with simvastatin","volume":"349","author":"Giordano","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.nmd.2013.09.011_b0330","first-page":"647","article-title":"Simvastatin-associated dermatomyositis","volume":"32","author":"Khattak","year":"1993","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.nmd.2013.09.011_b0335","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/mus.20127","article-title":"Dermatomyositis-like syndrome and HMG-CoA reductase inhibitor (statin) intake","volume":"30","author":"Vasconcelos","year":"2004","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2013.09.011_b0340","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/S0002-9343(01)00711-2","article-title":"Atorvastatin induced dermatomyositis","volume":"110","author":"CJaPR","year":"2001","journal-title":"Am J Med"},{"key":"10.1016\/j.nmd.2013.09.011_b0345","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1445-5994.1995.tb02870.x","article-title":"Dermatomyositis with lung involvement in a patient treated with simvastatin","volume":"25","author":"Hill","year":"1995","journal-title":"Aust N Z J Med"},{"key":"10.1016\/j.nmd.2013.09.011_b0350","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1136\/pgmj.72.853.694","article-title":"Lovastatin-associated dermatomyositis","volume":"72","author":"Rodriguez-Garcia","year":"1996","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.nmd.2013.09.011_b0355","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.revmed.2005.07.005","article-title":"Pravastatin-induced dermatomyositis","volume":"26","author":"Zuech","year":"2005","journal-title":"Rev Med Intern"},{"key":"10.1016\/j.nmd.2013.09.011_b0360","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1212\/01.WNL.0000145708.03876.C3","article-title":"Statin-associated exacerbation of myasthenia gravis","volume":"63","author":"Cartwright","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2013.09.011_b0365","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/01.md.0000209337.59874.aa","article-title":"Statin-associated myasthenia gravis: report of 4 cases and review of the literature","volume":"85","author":"Purvin","year":"2006","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.nmd.2013.09.011_b0370","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/j.1365-2125.2008.03248.x","article-title":"Pharmacogenomic studies of the anticancer and immunosuppressive thiopurines mercaptopurine and azathioprine","volume":"66","author":"Hawwa","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.nmd.2013.09.011_b0375","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/clpt.2012.96","article-title":"Pharmacogenomics knowledge for personalized medicine","volume":"92","author":"Whirl-Carrillo","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.nmd.2013.09.011_b0380","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nrd2423","article-title":"Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges","volume":"6","author":"Wilke","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.nmd.2013.09.011_b0385","unstructured":"FDA, News, Release. FDA approves updated warfarin (Coumadin) prescribing information. 2007 [cited 2012 10.12.12]; Available from: http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/2007\/ucm108967.htm."},{"key":"10.1016\/j.nmd.2013.09.011_b0390","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0021-9150(96)06031-5","article-title":"A comparative study of the efficacy of simvastatin and gemfibrozil in combined hyperlipoproteinemia: prediction of response by baseline lipids, apo E genotype, lipoprotein(a) and insulin","volume":"129","author":"Nestel","year":"1997","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.nmd.2013.09.011_b0395","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0021-9150(94)05439-P","article-title":"Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy","volume":"113","author":"Ordovas","year":"1995","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.nmd.2013.09.011_b0400","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0021-9150(01)00410-5","article-title":"Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner","volume":"158","author":"Pedro-Botet","year":"2001","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.nmd.2013.09.011_b0405","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/S0735-1097(00)00918-9","article-title":"Apolipoprotein E genotypes and response of plasma lipids and progression-regression of coronary atherosclerosis to lipid-lowering drug therapy","volume":"36","author":"Ballantyne","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.nmd.2013.09.011_b0410","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1001\/jama.291.23.2821","article-title":"Pharmacogenetic study of statin therapy and cholesterol reduction","volume":"291","author":"Chasman","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.nmd.2013.09.011_b0415","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/(SICI)1098-2825(2000)14:3<125::AID-JCLA7>3.0.CO;2-S","article-title":"Lipid-lowering response of the HMG-CoA reductase inhibitor fluvastatin is influenced by polymorphisms in the low-density lipoprotein receptor gene in Brazilian patients with primary hypercholesterolemia","volume":"14","author":"Salazar","year":"2000","journal-title":"J Clin Lab Anal"},{"key":"10.1016\/j.nmd.2013.09.011_b0420","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/sj.tpj.6500195","article-title":"Haplotypes of the cholesteryl ester transfer protein gene predict lipid-modifying response to statin therapy","volume":"3","author":"Winkelmann","year":"2003","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.nmd.2013.09.011_b0425","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0735-1097(99)00535-5","article-title":"Interactions between angiotensin-I converting enzyme insertion\/deletion polymorphism and response of plasma lipids and coronary atherosclerosis to treatment with fluvastatin: the lipoprotein and coronary atherosclerosis study","volume":"35","author":"Marian","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.nmd.2013.09.011_b0430","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s11883-005-0007-3","article-title":"Pharmacogenetics of response to statins: where do we stand?","volume":"7","author":"Maitland-van der Zee","year":"2005","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.nmd.2013.09.011_b0435","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/00125817-200203000-00002","article-title":"A comprehensive review of genetic association studies","volume":"4","author":"Hirschhorn","year":"2002","journal-title":"Genet Med"},{"key":"10.1016\/j.nmd.2013.09.011_b0440","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1517\/14656566.2011.563734","article-title":"Pharmacogenomics and adverse drug reactions: the case of statins","volume":"12","author":"Giorgi","year":"2011","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.nmd.2013.09.011_b0445","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1002\/acr.21671","article-title":"Increased frequency of DRB1\u221711:01 in anti-hydroxymethylglutaryl-coenzyme A reductase-associated autoimmune myopathy","volume":"64","author":"Mammen","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.nmd.2013.09.011_b0450","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/BOR.0b013e328314b7b4","article-title":"Genetic predisposition to statin myopathy","volume":"20","author":"Vladutiu","year":"2008","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.nmd.2013.09.011_b0455","doi-asserted-by":"crossref","first-page":"787","DOI":"10.2217\/14622416.8.7.787","article-title":"Role of OATP transporters in the disposition of drugs","volume":"8","author":"Niemi","year":"2007","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.nmd.2013.09.011_b0460","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/tpj.2009.54","article-title":"The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy","volume":"10","author":"Romaine","year":"2010","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.nmd.2013.09.011_b0465","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/clpt.2009.197","article-title":"Transporter pharmacogenetics and statin toxicity","volume":"87","author":"Niemi","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.nmd.2013.09.011_b0470","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.jacc.2009.04.053","article-title":"The SLCO1B1\u22175 genetic variant is associated with statin-induced side effects","volume":"54","author":"Voora","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.nmd.2013.09.011_b0475","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1097\/01.fpc.0000230416.82349.90","article-title":"SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid","volume":"16","author":"Pasanen","year":"2006","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.nmd.2013.09.011_b0480","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.clpt.2006.06.010","article-title":"SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin","volume":"80","author":"Niemi","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.nmd.2013.09.011_b0485","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","article-title":"SLCO1B1 variants and statin-induced myopathy\u2013a genomewide study","volume":"359","author":"SEARCH CG","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2013.09.011_b0490","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/clpt.2010.255","article-title":"Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study","volume":"89","author":"Donnelly","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.nmd.2013.09.011_b0495","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2133\/dmpk.19.453","article-title":"A novel variant allele of OATP-C (SLCO1B1) found in a Japanese patient with pravastatin-induced myopathy","volume":"19","author":"Morimoto","year":"2004","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.nmd.2013.09.011_b0500","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/clpt.2012.57","article-title":"The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy","volume":"92","author":"Wilke","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.nmd.2013.09.011_b0505","unstructured":"FDA. FDA: Limit Use of 80 mg Simvastatin. Consumer updates 2011 04-17-2013 [cited 2013 03-30-2013]; http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm256581.htm%5D."},{"key":"10.1016\/j.nmd.2013.09.011_b0510","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.clpt.2005.08.003","article-title":"The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment","volume":"78","author":"Fiegenbaum","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.nmd.2013.09.011_b0515","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.amjcard.2004.01.014","article-title":"Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner","volume":"93","author":"Kajinami","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.nmd.2013.09.011_b0520","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s002280050094","article-title":"In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors","volume":"50","author":"Transon","year":"1996","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.nmd.2013.09.011_b0525","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/425760a","article-title":"With your genes? Take one of these, three times a day","volume":"425","author":"Abbott","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.nmd.2013.09.011_b0530","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2165\/00129784-200404040-00005","article-title":"Genetic polymorphisms in cytochrome P450 enzymes: effect on efficacy and tolerability of HMG-CoA reductase inhibitors","volume":"4","author":"Vermes","year":"2004","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.nmd.2013.09.011_b0535","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/01213011-200506000-00007","article-title":"Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage","volume":"15","author":"Wilke","year":"2005","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.nmd.2013.09.011_b0540","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1097\/FPC.0b013e328012d0a9","article-title":"CYP2D6\u22174 polymorphism is associated with statin-induced muscle effects","volume":"17","author":"Frudakis","year":"2007","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.nmd.2013.09.011_b0545","first-page":"284","article-title":"Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences","volume":"60","author":"Sachse","year":"1997","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.nmd.2013.09.011_b0550","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S0009-9236(01)25429-0","article-title":"Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin","volume":"70","author":"Mulder","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.nmd.2013.09.011_b0555","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.phrs.2006.12.009","article-title":"Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin","volume":"55","author":"Zuccaro","year":"2007","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.nmd.2013.09.011_b0560","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0009-9236(03)00121-8","article-title":"Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers","volume":"74","author":"Kirchheiner","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.nmd.2013.09.011_b0565","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/00005344-200105000-00002","article-title":"Safety, tolerability, and pharmacokinetics of an extended-release formulation of fluvastatin administered once daily to patients with primary hypercholesterolemia","volume":"37","author":"Sabia","year":"2001","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.nmd.2013.09.011_b0570","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1017\/S0317167100007514","article-title":"A neuromuscular approach to statin-related myotoxicity","volume":"35","author":"Baker","year":"2008","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.nmd.2013.09.011_b0575","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1590\/S0004-282X2007000500020","article-title":"McArdle disease with rhabdomyolysis induced by rosuvastatin: case report","volume":"65","author":"Lorenzoni","year":"2007","journal-title":"Arq Neuropsiquiatr"},{"key":"10.1016\/j.nmd.2013.09.011_b0580","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1258\/000456303322326542","article-title":"The case of stainless statins","volume":"40","author":"Barth","year":"2003","journal-title":"Ann Clin Biochem"},{"key":"10.1016\/j.nmd.2013.09.011_b0585","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1258\/0004563041201554","article-title":"McArdle\u2019s disease diagnosed following statin-induced myositis","volume":"41","author":"Livingstone","year":"2004","journal-title":"Ann Clin Biochem"},{"key":"10.1016\/j.nmd.2013.09.011_b0590","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/j.1365-2796.2005.01515.x","article-title":"Statin-disclosed acid maltase deficiency","volume":"258","author":"Voermans","year":"2005","journal-title":"J Intern Med"},{"key":"10.1016\/j.nmd.2013.09.011_b0595","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/01.md.0000188565.48918.41","article-title":"Rhabdomyolysis: an evaluation of 475 hospitalized patients","volume":"84","author":"Melli","year":"2005","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.nmd.2013.09.011_b0600","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/mus.20567","article-title":"Genetic risk factors associated with lipid-lowering drug-induced myopathies","volume":"34","author":"Vladutiu","year":"2006","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2013.09.011_b0605","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/art.22100","article-title":"In vivo and in vitro characterization of skeletal muscle metabolism in patients with statin-induced adverse effects","volume":"55","author":"Guis","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2013.09.011_b0610","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/art.22487","article-title":"Statin-induced adverse effects and malignant hyperthermia susceptibility: comment on the article by Guis et al.","volume":"57","author":"Vladutiu","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2013.09.011_b0615","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ymgme.2011.07.001","article-title":"Genetic risk for malignant hyperthermia in non-anesthesia-induced myopathies","volume":"104","author":"Vladutiu","year":"2011","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.nmd.2013.09.011_b0620","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/FPC.0b013e328343dd7d","article-title":"Cerivastatin, genetic variants, and the risk of rhabdomyolysis","volume":"21","author":"Marciante","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.nmd.2013.09.011_b0625","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.pediatrneurol.2008.09.002","article-title":"Myotoxicity of lipid-lowering agents in a teenager with MELAS mutation","volume":"39","author":"Tay","year":"2008","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.nmd.2013.09.011_b0630","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1476-511X-6-7","article-title":"Genetic determinants of statin intolerance","volume":"6","author":"Oh","year":"2007","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.nmd.2013.09.011_b0635","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1086\/500092","article-title":"A mutation in para-hydroxybenzoate-polyprenyl transferase (COQ2) causes primary coenzyme Q10 deficiency","volume":"78","author":"Quinzii","year":"2006","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.nmd.2013.09.011_b0640","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ajhg.2008.09.002","article-title":"Mutations in LPIN1 cause recurrent acute myoglobinuria in childhood","volume":"83","author":"Zeharia","year":"2008","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.nmd.2013.09.011_b0645","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1136\/ard.2007.075523","article-title":"Increased exposure to statins in patients developing chronic muscle diseases: a 2-year retrospective study","volume":"67","author":"Sailler","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nmd.2013.09.011_b0650","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2353\/ajpath.2010.091140","article-title":"Statin therapy and the expression of genes that regulate calcium homeostasis and membrane repair in skeletal muscle","volume":"177","author":"Draeger","year":"2010","journal-title":"Am J Pathol"},{"key":"10.1016\/j.nmd.2013.09.011_b0655","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/mus.20871","article-title":"Physiogenomic association of statin-related myalgia to serotonin receptors","volume":"36","author":"Ruano","year":"2007","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2013.09.011_b0660","doi-asserted-by":"crossref","first-page":"865","DOI":"10.2217\/14622416.6.8.865","article-title":"Physiogenomic analysis links serum creatine kinase activities during statin therapy to vascular smooth muscle homeostasis","volume":"6","author":"Ruano","year":"2005","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.nmd.2013.09.011_b0665","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2174\/187152912801823138","article-title":"Role of genetic factors in statins side-effects","volume":"12","author":"Scarpini","year":"2012","journal-title":"Cardiovasc Hematol Disord Drug Targets"},{"key":"10.1016\/j.nmd.2013.09.011_b0670","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jclinepi.2009.09.006","article-title":"Expectations, validity, and reality in pharmacogenetics","volume":"63","author":"Limdi","year":"2010","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.nmd.2013.09.011_b0675","doi-asserted-by":"crossref","first-page":"858","DOI":"10.7326\/0003-4819-150-12-200906160-00009","article-title":"Narrative review: statin-related myopathy","volume":"150","author":"Joy","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.nmd.2013.09.011_b0680","first-page":"428","article-title":"Asymptomatic hypothyroidism and statin-induced myopathy","volume":"53","author":"Bar","year":"2007","journal-title":"Can Fam Physician"},{"key":"10.1016\/j.nmd.2013.09.011_b0685","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.trsl.2008.11.002","article-title":"Low serum 25 (OH) vitamin D levels (<32ng\/mL) are associated with reversible myositis-myalgia in statin-treated patients","volume":"153","author":"Ahmed","year":"2009","journal-title":"Transl Res"},{"key":"10.1016\/j.nmd.2013.09.011_b0690","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1515\/CCLM.2003.088","article-title":"Pharmacogenomics and pharmacogenetics of cholesterol-lowering therapy","volume":"41","author":"Schmitz","year":"2003","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.nmd.2013.09.011_b0695","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2165\/00003088-200544030-00005","article-title":"Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs","volume":"44","author":"Zhou","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.nmd.2013.09.011_b0700","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2147\/tcrm.1.1.3.53600","article-title":"Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4","volume":"1","author":"Zhou","year":"2005","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.nmd.2013.09.011_b0705","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/CRD.0b013e3181903b7f","article-title":"Antiretroviral and statin drug-drug interactions","volume":"17","author":"Ray","year":"2009","journal-title":"Cardiol Rev"},{"key":"10.1016\/j.nmd.2013.09.011_b0710","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1067\/mcp.2000.108507","article-title":"Plasma concentrations of active simvastatin acid are increased by gemfibrozil","volume":"68","author":"Backman","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.nmd.2013.09.011_b0715","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S0009-9236(03)00052-3","article-title":"Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance","volume":"73","author":"Kyrklund","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.nmd.2013.09.011_b0720","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.clpt.2003.12.014","article-title":"The effect of gemfibrozil on the pharmacokinetics of rosuvastatin","volume":"75","author":"Schneck","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.nmd.2013.09.011_b0725","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1067\/mcp.2001.115542","article-title":"Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate","volume":"69","author":"Kyrklund","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.nmd.2013.09.011_b0730","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/sj.clpt.6100098","article-title":"Amiodarone interacts with simvastatin but not with pravastatin disposition kinetics","volume":"81","author":"Becquemont","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.nmd.2013.09.011_b0735","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/j.1468-1331.2010.03012.x","article-title":"EFNS guidelines on the diagnostic approach to pauci- or asymptomatic hyperCKemia","volume":"17","author":"Kyriakides","year":"2010","journal-title":"Eur J Neurol"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896613009784?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896613009784?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:02:15Z","timestamp":1760774535000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896613009784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":147,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S0960896613009784"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2013.09.011","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Statin myotoxicity: A review of genetic susceptibility factors","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2013.09.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}